Dr Nicolas Girard on LUMINOSITY: Teliso-V Improves PROs in NSCLC
Nicolas Girard discusses Teliso-V's promising efficacy and manageable safety profile in c-Met–overexpressing, EGFR wild-type, nonsquamous NSCLC, with improved QOL and cancer-related symptoms like cough and chest pain, as reported in the LUMINOSITY trial. Patient-reported outcomes (PROs) show Teliso-V's benefits align with clinical data, though peripheral neuropathy requires monitoring.
Related Clinical Trials
Reference News
Nicolas Girard discusses Teliso-V's promising efficacy and manageable safety profile in c-Met–overexpressing, EGFR wild-type, nonsquamous NSCLC, with improved QOL and cancer-related symptoms like cough and chest pain, as reported in the LUMINOSITY trial. Patient-reported outcomes (PROs) show Teliso-V's benefits align with clinical data, though peripheral neuropathy requires monitoring.